Athanor Capital’s Krystal Biotech KRYS Stock Holding History

Athanor Capital’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,654	Closed	-$219K	–	945
2020 Q4	$219K	Buy	+3,654	New	+$182K	0.01%	641

Other funds holding KRYS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Athanor Capital's KRYS Position: Q1 2021 in Review

Athanor Capital sold out of Krystal Biotech (KRYS) in Q1 2021, closing a stake of 3,654 shares — an estimated $219K sold.

Athanor Capital first reported a position in KRYS in Q4 2020 and held it in 1 quarter. The position peaked at $219K in Q4 2020. 113 funds tracked by Wall St. Rank hold KRYS as of Q1 2021.

Athanor Capital reported no remaining Krystal Biotech position as of Q1 2021 after selling out during the quarter.
Athanor Capital sold 3,654 Krystal Biotech shares in Q1 2021, an estimated $219K.
Athanor Capital first reported a position in Krystal Biotech in Q4 2020 and held it in 1 quarter.
Athanor Capital's Krystal Biotech position peaked at $219K in Q4 2020.
113 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.